Malaria Vaccine.

reportActive / Technical Report | Accession Number: ADD011994 | Need Help?

Abstract:

The invention provides an antigenic protein consisting essentially of a merozoite polypeptide selected from the group consisting of an erythrocyte and merozoite binding protein derived form Plasmodium falciparum and erythrocyte and merozoite binding protein derived from Plasmodium vivax an erythrocyte and merozoite binding protein derived from Plasmodium ovalae and an erythrocyte and merozoite binding protein derived from Plasmodium malariae in purified form. The invention also provides a composition for the vaccination of a human against malaria consisting essentially of an erthrocyte and merozoite binding antigenic protein and a carrier therefore, the concentration of antigenic protein being sufficient to provide an immune protection of a human against malaria.

Author(s):
Camus, Daniel E.
Author Organization(s):
DEPARTMENT OF THE ARMY WASHINGTON DC
Descriptive Note:
Patent Application,
Pagination:
0012

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Availability: This Government-owned Invention Available For U.s. Licensing And, Possibly, For Foreign Licensing. Copy Of Application Available Ntis.

RECORD

Collection: TR
Identifying Numbers
Report Number(s):
PAT-APPL-780 750
 Subject Terms
Communities of Interest:
No COI(s) Identified
Descriptor(s):
*PATENT APPLICATIONS, *ANTIMALARIALS, *VACCINES, ANTIGENS, PROTEINS, INVENTIONS, MALARIA, CHEMICAL BONDS, MEROZOITES, PLASMODIUM FALCIPARUM, IMMUNITY, IMMUNIZATION
Field(s)/Group(s):
Pharmacology
Report Date:
1985 Sep 27